Audit: QRS - GLA for Health & Longevity
Audit conducted on 19/09/2026 04:29 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol doses (ER 367-371, 377), time-to-effect (ER 424), benefit/risk tier headings (ER 153-237, 261-303), contraindications (ER 341-345), interactions (ER 321-337), biomarker table (ER 454-462) and qualitative markers (ER 466-471) all trace to ER text. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Conflicted tiers carried across: Risks Low keeps “(conflicted)” for the seizure item (ER 285) and Benefits Low keeps “conflicted evidence for” for the five ⚠️ Conflicted entries (ER 193-227). DGLA target keeps the ER’s “No established target” wording (ER 458). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found. Pregnancy remains an avoid item rather than a caution, and the seizure signal stays framed as historical/conflicted as in ER 287 and 327. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Categories map one-to-one: stop_items from ER “Populations who should avoid GLA” (ER 341-345), caution_items from the ER interaction bullets (ER 321-337). No Benefit- or Risk-Modifying Factor (ER 242-252, 308-316) surfaces as a gate item. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PubMed IDs, NCT identifiers, study citations, expert names or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced; the ER’s named attributions (Life Extension, Zurier’s group, Wake Forest) are all dropped rather than reassigned. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, split-record register; the ER’s own conclusion phrasing carries into at_a_glance. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven (doses, ranges, biomarker targets) while remaining readable; tiering conveys evidence strength without hedging the actionable content. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Descriptive throughout; doses are presented as trial-derived ranges rather than instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative clinical direction. Protocol cells state what trials used, e.g. “The rheumatoid arthritis trial range” (line 461). |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Presents information only; no “recommend”, “advise”, “should” or “consider” appears in the QRS voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | Verified by search: no second-person pronoun occurs anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are either plain-language substitutes (at_a_glance uses “a second fat”, “calming signals”) or unavoidable biomarker names in the Monitoring table. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every item is a compressed phrase; benefits and risks are collapsed to semicolon-separated tier lines. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address; confirmed by the same pronoun search as 2.6. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content is pitched at readers prepared to dose to trial levels and run a fatty-acid panel. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Retains the high-burden path: 1.4-2.8 g/day of GLA requiring 6-14 g of borage oil (line 461). |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nothing is simplified to general-population framing; the capsule-burden and monitoring demands are kept intact. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The longevity-relevant null is surfaced in at_a_glance (“Blood levels show no link to longevity”), mirroring the ER’s deflating conclusion at ER 493. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not occur; the longevity framing is used instead. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No colloquial or consumer-grade terms. No route-of-administration lay phrasing; “supplement”, “capsule” and “dose” are used in the ER’s own register. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings verified in source: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, the four tier labels, and “Marker” / “Target” / “Why”. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Diff against the template confirms every template span is present; marker_#* is expanded to marker_1..7 and qualitative_item# to items 1-6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A full diff against QRS.html shows changes confined to span contents plus the 13.5-mandated display:none on risks_medium. The website=”…” spans, CSS, comments and structure are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section is empty and the ER uses no empty-state phrasing; the empty Medium risk tier is governed by 13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER bold labels verbatim: “Standard anti-inflammatory dose”, “Disease-level dose”, “Neuropathy dose” (ER 367-371). Interaction items reuse the ER bold labels verbatim (ER 321-337). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No paraphrased or invented labels; marker names match the ER biomarker column exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators anywhere in the file; tiering is conveyed by bold labels and CSS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the per-section budget: benefits and risks reduced to one line per tier, contraindications to five short items, monitoring cadence to a single sentence. No content is carried at ER length. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens on line 2, immediately after <!doctype html> and before any other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening — on line 3 and closing — on line 13, with the permitted descriptive text preceding it. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block is an HTML comment and none of its values are echoed on the sheet other than those required by 6.3 and 6.4. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed and unquoted except duration: “00:03”, which contains a colon and therefore requires quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: gla_2026-0919-0004_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.9.11, matching the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0919-0418, in the required YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: gla_2026-0919-0004_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed alongside 5.4; no stray whitespace or unnecessary quoting in any value. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | page_title is “GLA for Health & Longevity - Quick Reference Sheet”, the ER canonical_topic (ER 8) with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic is “GLA for Health & Longevity”, entity-encoded as required. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date is 09/19/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0919-0418. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model is “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the template’s own date, review link, AI4L link and model name. No badge, alternate-names line, audit date or variant marker was added. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER conclusion (ER 489-493) into the conversion mechanism, the two indications that hold, the omega-3 pairing requirement and the longevity null. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words, measured programmatically against the 60-word limit. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the four sentences maps to a distinct conclusion passage: ER 489, ER 491, ER 491, ER 493. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms and no technical classifications. GLA, DGLA, EPA, arachidonic acid and desaturase are all avoided in favour of “a seed-oil fat”, “a second fat”, “a fish-oil partner” and “the inflammation-driving branch”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks or statistical results; “doses well above supplement labels” is qualitative. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER “Populations who should avoid GLA” list inside Key Interactions & Contraindications (ER 341-345). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-populations appear as stop_items, one per ER bullet, in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each of the five items is a discrete <li></li> inside the stop_items span (lines 542-546). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale is stripped: the pregnancy item drops “where evening primrose oil is used to soften the cervix” (ER 343) and the liver item drops “because of pyrrolizidine alkaloid exposure” (ER 345). No dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Qualifiers preserved: the 50 × 10⁹/L platelet threshold, the 14-day surgical window, the 37-week gestational point, the three source plants and Child-Pugh Class B or C are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in the contraindication bullets. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is correctly not empty; the ER names five populations that should avoid GLA. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no empty-state HTML comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER Key Interactions & Contraindications bullets (ER 321-337). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All nine ER interaction bullets are represented, and none duplicates a contraindication: the surgical item carries only the procedure examples (colonoscopy with biopsy, epidural placement) that the elective-surgery contraindication does not cover. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each of the nine items is a discrete <li></li> inside the caution_items span (lines 554-562). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic rationale is stripped throughout: the delta-5 desaturase explanation (ER 331, 335), the prostaglandin E1 route (ER 325) and every mitigation step (ER 321-337) are dropped. The retained semicolon clauses are interaction-type labels, not explanations. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved for all seven drug-class items, plus the 400 IU vitamin E threshold and the procedure examples. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in the interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is correctly not empty; the ER names nine interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no empty-state HTML comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Drawn from the ER Therapeutic Protocol section (ER 365-391). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three dosing bullets are selected over the ER’s mechanistic and modifier bullets, which is the correct actionable subset. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol names thirteen bullets, well above three, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action cells carry ER-derived content; the sub cells add the omega-3 pairing and meal timing (ER 367, 377), the borage-oil burden (ER 369) and the six-to-twelve-month trial duration (ER 371). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Diabetic neuropathy, rheumatoid arthritis and skin barrier are the three time-to-effect aspects the ER names (ER 424). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered by benefit magnitude: neuropathy and rheumatoid arthritis are the two High benefits (ER 153, 159), skin barrier is a Low benefit (ER 205). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names three distinct time-to-effect aspects, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time cells are populated from ER 424: 6-12 months, 6 months, 2 months, with the eight-week premature-judgement note carried verbatim. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at ER 424, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Drawn from the ER Expected Benefits section (ER 147-237). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier spans are present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER subheadings alone. Effect sizes, confidence intervals, sample sizes and mechanisms from the Magnitude paragraphs are all dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content appears in any benefits tier. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain entries, so no span needs to be hidden. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Drawn from the ER Potential Risks & Side Effects section (ER 255-303). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier spans are present; three populated and risks_medium correctly hidden. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER subheadings alone; the pooled event rates, confidence intervals and case-report detail from the Magnitude paragraphs are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No ER parenthetical content is carried through; the only parenthesis is the conflicted marker required by 1.2. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_medium carries style=”display: none” with an HTML comment citing the ER’s “No risk sits at Medium” (ER 275), rather than empty-state phrasing (lines 577-579). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER Monitoring Protocol & Defining Success biomarker table (ER 454-462). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarkers are listed in ER order, with targets copied exactly: Omega-3 Index, arachidonic acid to EPA ratio, DGLA, hs-CRP, triglycerides, INR and alanine aminotransferase. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | monitoring_cadence carries the ER’s full schedule from ER 452, including the clotting-time exception. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER qualitative-marker list inside Monitoring Protocol & Defining Success (ER 466-471). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are listed verbatim, one per <li>. |
Issues 19/09/2026 04:29
Pass rate 100.00%. No issues found.
Issues 19/09/2026 04:23
- 9.2 — Procedure interaction dropped: The ER’s “Surgical and dental procedures” interaction bullet (ER line 337), covering any intervention with bleeding risk including colonoscopy with biopsy and epidural placement, is missing from [caution_items]; the Contraindications gate only covers elective surgery within 14 days.
- 4.2 / 4.3 — ER bold label replaced: Key Interactions item 4 (QRS line 557) uses “Aspirin and non-steroidal anti-inflammatory drugs” instead of the ER’s bold label “Over-the-counter medications” (ER line 329), while the other seven gate items use ER labels verbatim.
Fixes 19/09/2026 04:23
- 9.2 — Procedure interaction restored: Added a ninth [caution_items] entry, “Surgical and dental procedures (colonoscopy with biopsy, epidural placement)”, carrying the ER interaction bullet the gate had dropped.
- 4.2 / 4.3 — ER bold label restored: Replaced the paraphrased Key Interactions label “Aspirin and non-steroidal anti-inflammatory drugs (ibuprofen, naproxen)” with the ER’s own label as “Over-the-counter medications (aspirin, ibuprofen, naproxen)”.